Research
Metabolic adaptation
Incretin-based therapies such as GLP-1 RA improve symptoms, exercise capacity, congestion, and reduce heart failure events in obesity-related HFpEF.
Practitioners may consider incretin-based therapies as a treatment option for improving outcomes in patients with obesity-related HFpEF.
StrongSupportsmedium confidence
In obesity-related HFpEF, emerging data suggest GLP-1 RA and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists (also called incretin-based therapies) improve symptoms, exercise capacity, congestion, and reduce heart failure events.
Why this rating
Based on emerging data suggesting significant clinical benefits.
Source
Reframing obesity-related HFpEF as a multiorgan syndrome: incretin-based therapies and imaging endpoints
Masliza Mahmod et al. · Heart Failure Reviews · 2026
DOI 10.1007/s10741-026-10629-z
other
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Metabolic adaptation
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →